POEGMA-Aptamer Conjugates Eliminate Anti-PEG Immune Responses
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
RNA aptamers face significant delivery challenges due to the induction of anti-PEG antibody responses and immune reactions when conjugated with polyethylene glycol (PEG), which can lead to severe infusion reactions and limit their clinical use, especially since pre-existing PEG antibodies are prevalent in up to 70% of humans.
Innovation Solution
Conjugating RNA aptamers with a poly[oligo(ethylene glycol) methyl ether methacrylate] (POEGMA) instead of PEG, which has a poly(methyl methacrylate) backbone and side chains of 1 to 6 ethylene glycol monomers, to create a conjugate that does not induce an anti-POEGMA antibody response and is non-reactive with pre-existing PEG antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If RNA aptamers are conjugated with polyethylene glycol (PEG) to improve delivery, then delivery challenges are alleviated, but anti-PEG antibody responses are induced and severe infusion reactions occur
Solution Approach 1:
The patent changes the chemical parameters of the PEG conjugate by using POEGMA (poly[oligo(ethylene glycol) methyl ether methacrylate]) instead of conventional PEG. This parameter change modifies the polymer structure to have a poly(methyl methacrylate) backbone with oligo(ethylene glycol) side chains, which eliminates the induction of anti-PEG antibodies while maintaining the delivery benefits.
Solution Approach 2:
The patent employs a composite polymer structure combining poly(methyl methacrylate) backbone with oligo(ethylene glycol) side chains (POEGMA). This composite material approach creates a hybrid structure that provides both the delivery advantages of PEG and the non-immunogenic properties needed to avoid antibody responses.
2Reliability
If PEG is used to conjugate RNA aptamers to enhance therapeutic effect, then delivery is improved, but pre-existing PEG antibodies in 70% of humans trigger immune reactions
Solution Approach 1:
The patent modifies the chemical parameters of the conjugate by replacing PEG with POEGMA, changing the polymer's immunogenic properties. This parameter change ensures that the conjugate does not react with pre-existing PEG antibodies present in 70% of the human population, thereby eliminating a major barrier to therapeutic reliability.
3Ease of operation
If PEG-RNA conjugates are used for therapy, then delivery challenges are overcome, but thymus-independent antigen response is initiated making immune response unpredictable
Solution Approach 1:
The patent changes the chemical composition parameter from PEG to POEGMA, which fundamentally alters the antigen response profile. This parameter change transitions the conjugate from initiating thymus-independent antigen responses to a more predictable immune response profile, thereby improving immune response predictability while maintaining delivery efficacy.
Data Source
AI summary
Disclosed are POEGMA-aptamer conjugates with a reduced or eliminated host-immune response. An example conjugate includes an aptamer conjugated to a POEGMA having a plurality of side chains, where each side chain includes 1 to 6 monomers of ethylene glycol repeated in tandem. Also disclosed are methods of making the conjugate and methods of using the conjugate. An example method of use includes a method of controlling coagulation in a subject.